{"DataElement":{"publicId":"7423119","version":"1","preferredName":"First Cytomegalovirus Reactivation End Immunosuppressive Therapy Type","preferredDefinition":"Text that represents the kind of immunosuppression agent used at the end of the first CMV reactivation event.","longName":"CMVRC1_END_IMM_TX_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"7421697","version":"1","preferredName":"Immunosuppressive Therapy First Cytomegalovirus Reactivation Finding End","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes._Preceding all others in time or space or degree._A laboratory test result indicating that a previously latent cytomegalovirus infection has become an active infection._The point or place at which something terminates in time, space, or extent.","longName":"2854866v1.0:7421958v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2854866","version":"1","preferredName":"Immunosuppressive Therapy","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","longName":"C15261","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65C9E4D1-CBFF-C2BB-E040-BB89AD430C4B","latestVersionIndicator":"Yes","beginDate":"2009-03-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-03-23","modifiedBy":"ONEDATA","dateModified":"2009-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7421958","version":"1","preferredName":"First Cytomegalovirus Reactivation Finding End","preferredDefinition":"Preceding all others in time or space or degree.:A laboratory test result indicating that a previously latent cytomegalovirus infection has become an active infection.:The point or place at which something terminates in time, space, or extent.","longName":"C25509:C148545:C25496","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytomegalovirus Reactivation Finding","conceptCode":"C148545","definition":"A laboratory test result indicating that a previously latent cytomegalovirus infection has become an active infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF715831-7DA3-6EF1-E053-4EBD850AC09D","latestVersionIndicator":"Yes","beginDate":"2020-09-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-16","modifiedBy":"ONEDATA","dateModified":"2020-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF624ABC-C945-77C9-E053-4EBD850ACDA9","latestVersionIndicator":"Yes","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"HARTLEYG","dateModified":"2020-10-02","changeDescription":"Created for NCI-INC0519249 - BK and CMV qns curation 9.11.20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3233634","version":"1.1","preferredName":"Immunosuppressive Therapy Type","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes._Type; a subdivision of a particular kind of thing.","longName":"IMMSUPR_TX_TP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Tacrolimus","valueDescription":"Tacrolimus","ValueMeaning":{"publicId":"3305284","version":"1","preferredName":"Tacrolimus","longName":"3305284","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7062-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5F00F1-C777-030D-E053-4EBD850A7800","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Mycophenolate Mofetil","valueDescription":"Mycophenolate Mofetil","ValueMeaning":{"publicId":"3253642","version":"1","preferredName":"Mycophenolate Mofetil","longName":"3253642","preferredDefinition":"The mopholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-79F9-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5F00F1-C78B-030D-E053-4EBD850A7800","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"5127411","version":"1","preferredName":"Sirolimus","longName":"5127411","preferredDefinition":"A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamune blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamune was previously called rapamycin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA4E-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5F00F1-C76D-030D-E053-4EBD850A7800","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Steroids","valueDescription":"Steroid Compound","ValueMeaning":{"publicId":"4791933","version":"1","preferredName":"Steroid Compound","longName":"4791933","preferredDefinition":"A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Steroid Compound","conceptCode":"C843","definition":"Compounds possessing the skeleton of cyclopenta[a]phenanthrene or a skeleton derived therefrom by one or more bond scissions or ring expansions or contractions. Methyl groups are normally present at C-10 and C-13. An alkyl side chain may also be present at C-17.  They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"13B58EB7-C641-67FA-E050-BB89AD434046","latestVersionIndicator":"Yes","beginDate":"2015-04-14","endDate":null,"createdBy":"COLBERTM","dateCreated":"2015-04-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5F00F1-C795-030D-E053-4EBD850A7800","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-1066-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-1070-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-107A-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Anti-TNF Therapy","valueDescription":"Anti-Tumor Necrosis Factor Therapy","ValueMeaning":{"publicId":"3233636","version":"1","preferredName":"Anti-Tumor Necrosis Factor Therapy","longName":"3233636","preferredDefinition":"Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Tumor Necrosis Factor Therapy","conceptCode":"C15577","definition":"Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A27C18C9-DC1E-820E-E040-BB89AD432300","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-1084-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Azathioprine","valueDescription":"Azathioprine","ValueMeaning":{"publicId":"3128751","version":"1","preferredName":"Azathioprine","longName":"3128751","preferredDefinition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azathioprine","conceptCode":"C290","definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F3C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-108E-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"2757911","version":"1","preferredName":"Cyclophosphamide","longName":"2757911","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83F7-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-1098-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"3233637","version":"1","preferredName":"Methotrexate","longName":"3233637","preferredDefinition":"An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A27C18C9-DC55-820E-E040-BB89AD432300","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-10A2-5343-E053-4EBD850AD98A","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF5EC98C-10AC-5343-E053-4EBD850AD98A","beginDate":"2019-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3233633","version":"1","preferredName":"Immunosuppressive Therapy Type","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.:Type; a subdivision of a particular kind of thing.","longName":"C15261:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A27C18C9-DBD6-820E-E040-BB89AD432300","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-04","modifiedBy":"ONEDATA","dateModified":"2011-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF5EC98C-1050-5343-E053-4EBD850AD98A","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"COOPERM","dateModified":"2020-09-15","changeDescription":"Released per approval by B. McClure-Shimel. mc 5/12/11 Versioned to extend max length and to add PVs for CCR. mc 9.15.20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Immunosuppression at end of r","type":"Preferred Question Text","description":"Immunosuppression at end of reactivation event #1","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF71263D-C08A-1831-E053-4EBD850A951D","latestVersionIndicator":"Yes","beginDate":"2020-09-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-16","modifiedBy":"HARTLEYG","dateModified":"2020-10-02","changeDescription":"Created for NCI-INC0519249 - BK and CMV qns curation 9.11.20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}